文献速递甲状腺疾病

2302例原发性治疗反应极佳的分化型甲状腺癌患者复发频率分析

The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该单中心回顾性分析纳入24年间2302例对初始治疗反应极佳(ExR)的分化型甲状腺癌(DTC)患者,32例(1.4%)出现真性复发,5、10、15、20、24年累积复发率分别为1.2%、1.9%、2.5%、2.9%、2.9%。乳头状甲状腺癌(PTC)复发者更年轻、肿瘤更大、有淋巴结转移、切除不完全、ATA危险度更高且更多接受131I治疗。结论认为真性复发罕见,N0/Nx的PTC患者可结束肿瘤随访,而N1及PDTC、OTC、FTC患者应继续肿瘤随访。

要点

  • 2302例ExR的DTC患者中32例(1.4%)发生真性复发,5年累积复发率1.2%。
  • 复发多见于年轻、肿瘤较大、淋巴结转移、切除不完全、ATA高危及接受131I治疗的PTC患者。
  • 超声联合细针穿刺细胞学是检出局部复发最有效方法,18F-FDG PET用于远处转移。

核心结论

  • DTC患者真性复发罕见;对初始治疗反应极佳且为N0/Nx的PTC患者可结束肿瘤随访,而N1及PDTC、OTC、FTC患者即使反应极佳也应继续肿瘤随访。

研究设计与样本

  • 单中心24年间连续纳入2302例对初始治疗反应极佳(ExR)的DTC患者的回顾性分析。

主要发现

  • 2302例DTC患者中32例(1.4%)出现复发。
  • 复发PTC患者更常见年轻年龄(P=0.0182)、更大肿瘤(P=0.0013)、淋巴结转移(P=0.0013)、切除不完全(P=0.0446)、更高ATA危险度(P=0.0002)及更多接受131I治疗(P=0.0203)。
  • 术后5、10、15、20、24年累积复发率分别为1.2%、1.9%、2.5%、2.9%、2.9%。
  • 按组织学类型,累积复发率PDTC最高,OTC和FTC次之,PTC最低;大多数复发发生在观察前5年内。
  • 检出局部复发最有效方法为超声联合细针穿刺细胞学,检出远处转移最有效方法为18F-FDG PET。

临床怎么用

  • 作者认为,对初始治疗反应极佳且为N0/Nx的PTC患者可结束肿瘤随访。
  • 作者认为,对初始治疗反应极佳但为N1的DTC患者及PDTC、OTC、FTC患者应继续肿瘤随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Discrepant data on the recurrence rate of differentiated thyroid cancer (DTC) are reported. OBJECTIVE: To evaluate the frequency and risk factors of true recurrence in DTC patients with excellent responses (ExR) to initial therapy. METHODS: A retrospective analysis of the 2302 consecutive DTC patients with ExR to primary therapy, treated during 24 years at single center. The percentage of recurrence and cumulative recurrence rate (CRR) were analyzed. Risk factors for recurrence for patients with papillary thyroid cancer (PTC) were investigated and methods for establishing a diagnosis of recurrence were evaluated. RESULTS: Of DTC patients, 32 (1.4%) experienced recurrence. PTC patients with recurrence were more likely to have younger age (P = .0182), larger tumor size (P = .0013), lymph node metastases (P = .0013), incomplete resection (P = .0446), higher ATA risk (P = .0002), and had more frequently been treated with 131I (P = .0203). CRRs at 5, 10, 15, 20, and 24 years after surgery were 1.2%, 1.9%, 2.5%, 2.9%, and 2.9%, respectively. The CRRs according to histological type were highest for poorly differentiated thyroid cancer (PDTC), lower for oncocytic (OTC) and follicular thyroid cancer (FTC), and lowest for PTC. Most recurrences occurred within the first 5 years of observation. The most effective method for detecting local recurrence was ultrasonography with fine needle aspiration cytology, and for distant metastases, 18F-FDG PET. CONCLUSION: True recurrence is rare in DTC patients. PTC patients with ExR to primary therapy and N0/Nx can be dismissed from oncological follow-up. Despite ExR to primary therapy, DTC patients with N1, and PDTC, OTC, FTC should remain under oncological follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pałyga I, Rumian M, Kosel A, et al. The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy. J Clin Endocrinol Metab. 2024. PMID: 37768152. doi:10.1210/clinem/dgad571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。